The U.S. District Court for the Western District of Pennsylvania has entered a consent decree prohibiting Ranier’s Rx Laboratory Inc. from manufacturing or distributing compounded drugs until they comply with the Federal Food, Drug, and Cosmetic Act and Food and Drug Administration regulations, the FDA announced yesterday. A complaint filed with the consent decree alleges that the company’s purportedly sterile drug products were made under insanitary conditions. FDA last year alerted health care providers and patients not to use those products.

Related News Articles

Headline
The Centers for Disease Control and Prevention this week announced an anticipated shortage of Aplisol, one of two TB skin tests licensed by the Food and Drug…
Headline
A federal court in Texas yesterday ordered Pharm D Solutions to stop producing or distributing compounded drugs intended to be sterile until the company…
Headline
The Food and Drug Administration Friday issued final guidance clarifying how sponsors may show that a proposed biosimilar product is interchangeable with a…
Headline
The House Judiciary Committee yesterday approved by voice vote the Creating and Restoring Equal Access to Equivalent Samples Act (H.R. 965).
Headline
Civica Rx, the not-for-profit generic drug company, officially opened its headquarters last week in Lehi, Utah.
Headline
The Food and Drug Administration plans to revise its 2016 draft compounding guidance for hospital and health system pharmacies.